Xvivo Perfusion AB (LTS:0RKL)
kr 471.13141 -2.4818 (-0.52%) Market Cap: 15.12 Bil Enterprise Value: 14.69 Bil PE Ratio: 73.15 PB Ratio: 7.28 GF Score: 89/100

Q1 2021 Xvivo Perfusion AB Earnings Call Transcript

Apr 21, 2021 / 12:00PM GMT
Release Date Price: kr302 (+3.60%)
Operator

Ladies and gentlemen, welcome to the Xvivo Group interim report Q1 2021. (Operator Instructions) I will now hand it over to CEO, Dag Andersson. Please go ahead with your meeting.

Dag Andersson;publ;President;CEO
Xvivo Perfusion AB

()-&

Thank you very much for the introduction. So dear all, welcome to the first quarterly telephone conference 2021. And I am happy to present to you, together with my CFO, Kristoffer Nordstrom.

And as mentioned in the quarterly report released this morning, the year has started well for XVIVO and quarter 1 was positive from many different aspects. And both sales margins, EBITDA showed positive performance or very positive performance, sales up 38% in the quarter. We had a gross margin of 75%, and EBITDA margin adjusted of 11%. And also worth mentioning strong organic growth of 10%.

And particularly positive was the development of thoracic machine perfusion sales, which increased by 45% versus same quarter last year. This is actually an outstanding number, bearing

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot